Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 66.7%Low 1 · 33.3%Moderate 0 · 0%High 0 · 0%

Summary of findings 2: PLD alone vs other conventional chemotherapy

Neurological (grade ≥ 3) · recurrent platinum‐resistant EOC

It is very uncertain whether summary of findings 2: PLD alone changes neurological (grade ≥ 3) compared with other conventional chemotherapy (very low certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1222 participants
Very low

Summary of findings 1: PLD with chemotherapy vs PLD alone

Neurological (grade ≥ 3) · recurrent platinum‐resistant EOC

Summary of findings 3: PLD with chemotherapy showed no clear difference in neurological (grade ≥ 3) compared with PLD alone (low certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
RR 1.4 [0.85, 2.31]
1 study · 663 participants
Low

Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy

Neurological (grade ≥ 3) · platinum‐sensitive recurrent EOC

It is very uncertain whether summary of findings 1: PLD with chemotherapy changes neurological (grade ≥ 3) compared with alternative combination chemotherapy (very low certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
RR 0.38 [0.2, 0.74]
4 studies · 1900 participants
Very low